

Sean J Pittock

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5334463/sean-j-pittock-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

279
papers

21,658
citations

70
h-index

143
g-index

295
ext. papers

26,361
ext. citations

8.3
avg, IF

6.86
L-index

#	Paper	IF	Citations
279	Autoimmune gastrointestinal dysmotility following SARS-CoV-2 infection successfully treated with intravenous immunoglobulin.. <i>Neurogastroenterology and Motility</i> , 2022 , e14314	4	2
278	Anti-Neuronal Nuclear Antibody 3 Autoimmunity targets Dachshund homolog 1.. <i>Annals of Neurology</i> , 2022 ,	9.4	1
277	OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 58, 103525	4	2
276	AQP4-IgG-seronegative patient outcomes in the N-MOMentum trial of inebilizumab in neuromyelitis optica spectrum disorder.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103356	4	2
275	Adenylate kinase 5 (AK5) autoimmune encephalitis: Clinical presentations and outcomes in three new patients.. <i>Journal of Neuroimmunology</i> , 2022 , 367, 577861	3.5	0
274	Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	2
273	Response to: Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. <i>CNS Spectrums</i> , 2021 , 26, 195-196	1.8	5
272	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 303-308	5	25
271	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211052656	2.56	1
270	Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations.. <i>Mayo Clinic Proceedings</i> , 2021 ,	6.4	2
269	Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder. <i>Neurology and Therapy</i> , 2021 , 1	4.6	5
268	LGI1 antibody encephalitis: acute treatment comparisons and outcome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	3
267	Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes. <i>Neurology</i> , 2021 ,	6.5	3
266	Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials. <i>Nature Reviews Neurology</i> , 2021 , 17, 759-773	15	9
265	Exposure to TNF inhibitors is rare at MOGAD presentation. <i>Journal of the Neurological Sciences</i> , 2021 , 120044	3.2	0
264	Spectrum of sublytic astrocytopathy in neuromyelitis optica. <i>Brain</i> , 2021 ,	11.2	5
263	Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 425-439	5.3	6

262	MOG-IgG1 and co-existence of neuronal autoantibodies. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1175-1186	5	6
261	Autoimmune Epilepsy Disorders 2021 , 249-273		1
260	Disability Outcomes in the N-MOMentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	6
259	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , 2021 , 89, 895-910	9.4	23
258	Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	11
257	Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 757-768	5.5	50
256	Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels. <i>Neurology</i> , 2021 ,	6.5	2
255	MOG-IgG Among Participants in the Pediatric Optic Neuritis Prospective Outcomes Study. <i>JAMA Ophthalmology</i> , 2021 , 139, 583-585	3.9	0
254	Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211011450	5	2
253	Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	2
252	Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 50, 102849	4	0
251	Clinical Utility of Antiretinal Antibody Testing. <i>JAMA Ophthalmology</i> , 2021 , 139, 658-662	3.9	5
250	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. <i>JAMA Neurology</i> , 2021 , 78, 741-746	17.2	23
249	Paraneoplastic cochleovestibulopathy: clinical presentations, oncological and serological associations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1181-1185	5.5	1
248	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 667-673	5	2
247	Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 630-635	5	9
246	SMART syndrome: retrospective review of a rare delayed complication of radiation. <i>European Journal of Neurology</i> , 2021 , 28, 1316-1323	6	4
245	Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 47, 102638	4	8

244	Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments. <i>Neurology</i> , 2021 , 96, e632-e639	6.5	11
243	Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. <i>Brain Communications</i> , 2021 , 3, fcaa233	4.5	11
242	Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 47, 102641 ⁴		10
241	Clinical spectrum of high-titre GAD65 antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	24
240	Seizures and memory impairment induced by patient-derived anti-N-methyl-D-aspartate receptor antibodies in mice are attenuated by anakinra, an interleukin-1 receptor antagonist. <i>Epilepsia</i> , 2021 , 62, 671-682	6.4	4
239	Paraneoplastic neurological syndrome: an evolving story. <i>Neuro-Oncology Practice</i> , 2021 , 8, 362-374	2.2	
238	Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis. <i>Stroke</i> , 2021 , 52, 645-654	6.7	4
237	Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker. <i>Annals of Neurology</i> , 2021 , 89, 1001-1010	9.4	10
236	Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. <i>Annals of Neurology</i> , 2021 , 89, 1088-1098	9.4	13
235	Musicogenic epilepsy: Expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity. <i>Epilepsia</i> , 2021 , 62, e76-e81	6.4	5
234	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. <i>Neurology</i> , 2021 , 97, e1097-e1109	6.5	17
233	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103080	4	2
232	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. <i>Neurology</i> , 2021 , 97, e1351-e1358	6.5	9
231	Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211038291	5	7
230	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology, The</i> , 2021 , 20, 762-772		37
229	CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. <i>Mayo Clinic Proceedings</i> , 2021 ,	6.4	4
228	Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	2
227	Investigating the immunopathogenic mechanisms underlying MOGAD. <i>Annals of Neurology</i> , 2021 ,	9.4	1

226	Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. <i>JAMA Neurology</i> , 2020 , 77, 937-946	17.2	37
225	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 44, 102251	4	46
224	Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7, e727	9.1	14
223	Contactin-1 autoimmunity: Serologic, neurologic, and pathologic correlates. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	7
222	High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by programmable phage display. <i>Brain Communications</i> , 2020 , 2, fcaa059	4.5	13
221	Synaptic autoimmunity: new insights into LGI1 antibody-mediated neuronal dysfunction. <i>Brain</i> , 2020 , 143, 1622-1625	11.2	2
220	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. <i>Neurology</i> , 2020 , 95, e111-e120	6.5	65
219	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. <i>Frontiers in Neurology</i> , 2020 , 11, 501	4.1	93
218	Use of diffusion-weighted imaging to distinguish seizure-related change from limbic encephalitis. <i>Journal of Neurology</i> , 2020 , 267, 3337-3342	5.5	8
217	International multicenter examination of MOG antibody assays. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	77
216	Autoimmune psychosis. <i>Lancet Psychiatry</i> , 2020 , 7, 122	23.3	1
215	GFAP IgG associated inflammatory polyneuropathy. <i>Journal of Neuroimmunology</i> , 2020 , 343, 577233	3.5	3
214	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 ,	5.5	13
213	Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR. <i>PLoS ONE</i> , 2020 , 15, e0242049	3.7	7
212	The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. <i>Acta Neuropathologica</i> , 2020 , 139, 875-892	14.3	95
211	The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 37, 101487	4	20
210	Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients. <i>JAMA Neurology</i> , 2020 , 77, 257-259	17.2	25
209	Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)?. <i>Neurology</i> , 2020 , 94, 85-88	6.5	15

208	CRMP5-IgG-Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy. <i>JAMA Neurology</i> , 2020 , 77, 255-256	17.2	14
207	Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. <i>Annals of Neurology</i> , 2020 , 87, 313-323	9.4	55
206	IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 324-326	5.5	0
205	Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 328-330	5.5	15
204	Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. <i>American Journal of Ophthalmology</i> , 2020 , 220, 110-114	4.9	13
203	Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. <i>Clinical Chemistry</i> , 2020 , 66, 1496-1509	5.5	15
202	Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. <i>JAMA Neurology</i> , 2020 , 77, 1420-1429	17.2	50
201	Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders. <i>JAMA Neurology</i> , 2020 , 77, 1572-1575	17.2	6
200	Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm. <i>Neurology</i> , 2020 , 95, e3002-e3011	6.5	6
199	GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin-Associated Ataxia and Neuropathy. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 904-909	2.2	4
198	Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder. <i>JAMA Neurology</i> , 2020 , 77, 1575-1577	17.2	24
197	Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes. <i>Neurology</i> , 2020 , 95, e2442-e2452	6.5	47
196	Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 177-188	5.5	24
195	Collapsin Response-Mediator Protein 5-Associated Retinitis, Vitritis, and Optic Disc Edema. <i>Ophthalmology</i> , 2020 , 127, 221-229	7.3	10
194	Optic neuritis in the era of biomarkers. <i>Survey of Ophthalmology</i> , 2020 , 65, 12-17	6.1	31
193	Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis. <i>Neuro-Ophthalmology</i> , 2020 , 44, 1-4	0.9	11
192	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019 , 394, 1352-1363	40	247
191	Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG. <i>Neurology</i> , 2019 , 93, e954-e963	6.5	24

190	Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. <i>Neurology</i> , 2019 , 93, e1732-e1741	6.5	36
189	Optical coherence tomography is highly sensitive in detecting prior optic neuritis. <i>Neurology</i> , 2019 , 92, e527-e535	6.5	37
188	Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 1021-1026	5.5	27
187	Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019 , 381, 614-625	59.2	314
186	GABA receptor autoimmunity: A multicenter experience. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e552	9.1	23
185	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. <i>Brain</i> , 2019 , 142, 1310-1323	11.2	75
184	Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability. <i>Epilepsia</i> , 2019 , 60, 367-369	6.4	21
183	A multicenter comparison of MOG-IgG cell-based assays. <i>Neurology</i> , 2019 , 92, e1250-e1255	6.5	76
182	A mouse model of seizures in anti-N-methyl-d-aspartate receptor encephalitis. <i>Epilepsia</i> , 2019 , 60, 452-463	4	27
181	Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 488-490	5.5	33
180	Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity. <i>Neurology</i> , 2019 , 93, e815-e822	6.5	28
179	Testing for Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG) in typical MS. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 35, 34-35	4	2
178	Paraneoplastic Neurologic Disease 2019 , 141-157		
177	Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis. <i>New England Journal of Medicine</i> , 2019 , 381, 47-54	59.2	85
176	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. <i>Neurology</i> , 2019 , 93, e414-e420	6.5	14
175	Amphiphysin-IgG autoimmune neuropathy: A recognizable clinicopathologic syndrome. <i>Neurology</i> , 2019 , 93, e1873-e1880	6.5	23
174	Reader response: Unintended consequences of Mayo paraneoplastic evaluations. <i>Neurology</i> , 2019 , 93, 606	6.5	3
173	Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6,	9.1	0

172	Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 1381-1383	5.5	14
171	Neurochondrin neurological autoimmunity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6,	9.1	17
170	Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 150-152	2.4	56
169	Episodic ataxia in CASPR2 autoimmunity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e536	9.1	6
168	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. <i>JAMA Neurology</i> , 2019 , 76, 301-309	17.2	141
167	Age is a critical determinant in recovery from multiple sclerosis relapses. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1754-1763	5	18
166	CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 1071-1080	5.9	28
165	Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial. <i>JAMA Ophthalmology</i> , 2018 , 136, 419-422	3.9	54
164	Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 1299-1304	6.4	17
163	MRI findings in glutamic acid decarboxylase associated autoimmune epilepsy. <i>Neuroradiology</i> , 2018 , 60, 239-245	3.2	16
162	Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e438	9.1	38
161	Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM. <i>Muscle and Nerve</i> , 2018 , 57, 1000-1005	3.4	9
160	ITPR1 autoimmunity: Frequency, neurologic phenotype, and cancer association. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e418	9.1	13
159	Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. <i>Annals of Neurology</i> , 2018 , 83, 166-177	9.4	273
158	GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies. <i>Orphanet Journal of Rare Diseases</i> , 2018 , 13, 55	4.2	14
157	Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis. <i>JAMA Neurology</i> , 2018 , 75, 892-895	17.2	13
156	Elevated LGI1-IgG CSF index predicts worse neurological outcome. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 646-650	5.3	20
155	Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. <i>Ophthalmology</i> , 2018 , 125, 1628-1637	7.3	59

154	LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 526-534	5.5	93
153	LGI1 and CASPR2 neurological autoimmunity in children. <i>Annals of Neurology</i> , 2018 , 84, 473-480	9.4	38
152	Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. <i>American Journal of Ophthalmology</i> , 2018 , 195, 8-15	4.9	171
151	Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. <i>Journal of Neuroimmunology</i> , 2018 , 323, 62-72	3.5	40
150	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. <i>JAMA Neurology</i> , 2018 , 75, 1355-1363	17.2	159
149	Autoimmune septin-5 cerebellar ataxia. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e474	9.1	23
148	Posttransplant autoimmune encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e497	9.1	17
147	Neuroimmune disorders of the central nervous system in children in the molecular era. <i>Nature Reviews Neurology</i> , 2018 , 14, 433-445	15	29
146	Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. <i>Neurology</i> , 2018 , 90, e103-e110	6.5	50
145	Breast cancer-related paraneoplastic neurologic disease. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 771-778	4.4	16
144	Purkinje cell cytoplasmic antibody type I (anti-Yo): predictive of gastrointestinal adenocarcinomas in men. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 1116-1117	5.5	11
143	Paraneoplastic neuronal intermediate filament autoimmunity. <i>Neurology</i> , 2018 , 91, e1677-e1689	6.5	32
142	Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD. <i>Neurology</i> , 2018 , 91, e1642-e1651	6.5	84
141	Population-based study of "no evident disease activity" in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e495	9.1	4
140	Antiepileptic drug therapy in autoimmune epilepsy associated with antibodies targeting the leucine-rich glioma-inactivated protein 1. <i>Epilepsia Open</i> , 2018 , 3, 348-356	4	21
139	Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 year. <i>Journal of Neuroimmunology</i> , 2018 , 321, 157-163	3.5	62
138	Association of Extension of Cervical Cord Lesion and Area Postrema Syndrome With Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2017 , 74, 359-361	17.2	28
137	Microtubule-associated protein 1B: Novel paraneoplastic biomarker. <i>Annals of Neurology</i> , 2017 , 81, 266-277	17.2	44

136	Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. <i>Annals of Neurology</i> , 2017 , 81, 298-309	9.4	200
135	Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. <i>Acta Neuropathologica</i> , 2017 , 133, 597-612	14.3	38
134	Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 218-225	5.5	40
133	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e343	9.1	36
132	Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. <i>Annals of Neurology</i> , 2017 , 82, 79-92	9.4	153
131	Predictive models in the diagnosis and treatment of autoimmune epilepsy. <i>Epilepsia</i> , 2017 , 58, 1181-1188	8.4	75
130	Calcium channel autoimmunity: Cerebellar ataxia and lambert-eaton syndrome coexisting. <i>Muscle and Nerve</i> , 2017 , 58, 29	3.4	5
129	Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). <i>Brain</i> , 2017 , 140, 2415-2425	11.2	106
128	PRES leading to the diagnosis of McArdle disease. <i>Journal of Clinical Neuroscience</i> , 2017 , 46, 62-64	2.2	
127	IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e385	9.1	104
126	Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1808-1817	5	27
125	B-cell-targeted therapies in relapsing forms of MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e405	9.1	8
124	Dacrystic seizures-a cry for help. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e372	9.1	2
123	Clinical-pathologic correlations in voltage-gated Kv1 potassium channel complex-subtyped autoimmune painful polyneuropathy. <i>Muscle and Nerve</i> , 2017 , 55, 520-525	3.4	17
122	Autoimmune Neurology of the Central Nervous System. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2017 , 23, 627-653	3	9
121	Autoimmune Encephalitis in the ICU: Analysis of Phenotypes, Serologic Findings, and Outcomes. <i>Neurocritical Care</i> , 2016 , 24, 240-50	3.3	42
120	A comparison of tissue-based and recombinant protein-based assays for detecting PCA-Tr/DNER-IgG. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e294	9.1	1
119	Autoantibody-Associated Central Nervous System Neurologic Disorders. <i>Seminars in Neurology</i> , 2016 , 36, 382-96	3.2	27

118	P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments. <i>Muscle and Nerve</i> , 2016 , 54, 220-7	3.4	58
117	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. <i>Annals of Neurology</i> , 2016 , 79, 437-47	9.1	102
116	Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e231	9.1	72
115	Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 862-72	5	51
114	Signal recognition particle immunoglobulin g detected incidentally associates with autoimmune myopathy. <i>Muscle and Nerve</i> , 2016 , 53, 925-32	3.4	4
113	Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes. <i>Neurology</i> , 2016 , 86, 1009-13	6.5	58
112	Demyelinating disease: NMO spectrum disorders: clinical or molecular classification?. <i>Nature Reviews Neurology</i> , 2016 , 12, 129-30	15	8
111	Neuromyelitis optica spectrum initially diagnosed as antiphospholipid antibody myelitis. <i>Journal of the Neurological Sciences</i> , 2016 , 361, 204-5	3.2	5
110	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016 , 263, 140-9	5.5	40
109	Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. <i>Annals of the New York Academy of Sciences</i> , 2016 , 1366, 20-39	6.5	127
108	Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. <i>Annals of Neurology</i> , 2016 , 79, 775-783	9.4	173
107	Introduction to autoimmune neurology. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 133, 3-14	3	15
106	Paraneoplastic and idiopathic autoimmune neurologic disorders: approach to diagnosis and treatment. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 133, 165-83	3	16
105	Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 133, 377-403	3	40
104	Current and future immunotherapy targets in autoimmune neurology. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 133, 511-36	3	3
103	Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis. <i>JAMA Neurology</i> , 2016 , 73, 1297-1307	17.2	206
102	Autoimmune dementias 2016 , 123-133		
101	Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. <i>Neurology</i> , 2015 , 85, 722-9	6.5	65

100	Psychiatric Autoimmunity: N-Methyl-D-Aspartate Receptor IgG and Beyond. <i>Psychosomatics</i> , 2015 , 56, 227-41	2.6	37
99	Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy. <i>Neurology: Clinical Practice</i> , 2015 , 5, 175-177	1.7	14
98	Autoimmune Epilepsy. <i>Seminars in Neurology</i> , 2015 , 35, 245-58	3.2	47
97	Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults. <i>JAMA Neurology</i> , 2015 , 72, 1304-12	17.2	65
96	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. <i>Neurology</i> , 2015 , 84, 148-58	6.5	39
95	Autoimmune and Paraneoplastic Neurological Disorders 2015 , 467-496		
94	Relapses and disability accumulation in progressive multiple sclerosis. <i>Neurology</i> , 2015 , 84, 81-8	6.5	75
93	Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. <i>JAMA Neurology</i> , 2015 , 72, 81-7	17.2	162
92	Monitoring oligoclonal immunoglobulins in cerebral spinal fluid using microLC-ESI-Q-TOF mass spectrometry. <i>Journal of Neuroimmunology</i> , 2015 , 288, 123-6	3.5	4
91	Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e161	9.1	120
90	Antibodies to AQP4 2014 , 605-611		0
89	DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. <i>Neurology</i> , 2014 , 83, 1797-803	6.5	180
88	Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. <i>Lancet Neurology</i> , 2014 , 13, 795-806	24.1	68
87	Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies. <i>Clinical and Experimental Neuroimmunology</i> , 2014 , 5, 175-187	0.4	15
86	Neural autoantibody clusters aid diagnosis of cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 3862-9	12.9	49
85	Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. <i>JAMA Neurology</i> , 2014 , 71, 48-54	17.2	44
84	Hydrocephalus in neuromyelitis optica. <i>Neurology</i> , 2014 , 82, 1841-3	6.5	18
83	Clinical reasoning: a 55-year-old man with weight loss, ataxia, and foot drop. <i>Neurology</i> , 2014 , 82, e214-96.5		3

82	The neurologic significance of celiac disease biomarkers. <i>Neurology</i> , 2014 , 83, 1789-96	6.5	42
81	Evaluation of aquaporin-4 antibody assays. <i>Clinical and Experimental Neuroimmunology</i> , 2014 , 5, 290-303	0.4	76
80	Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4. <i>JAMA Neurology</i> , 2014 , 71, 495-8	17.2	36
79	Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis. <i>JAMA Neurology</i> , 2014 , 71, 1433-6	17.2	47
78	Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. <i>JAMA Neurology</i> , 2014 , 71, 1025-9	17.2	49
77	NMDA receptor encephalitis causing reversible caudate changes on MRI and PET imaging. <i>Neurology: Clinical Practice</i> , 2014 , 4, 470-473	1.7	11
76	Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. <i>Lancet Neurology</i> , 2013 , 12, 554-62	24.1	278
75	Intractable nausea and vomiting from autoantibodies against a brain water channel. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 240-5	6.9	43
74	Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. <i>Journal of Autoimmunity</i> , 2013 , 40, 21-7	15.5	55
73	Autoimmune chorea in adults. <i>Neurology</i> , 2013 , 80, 1133-44	6.5	85
72	Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. <i>JAMA Neurology</i> , 2013 , 70, 229-34	17.2	153
71	Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. <i>Neurology</i> , 2013 , 81, 1197-204	6.5	157
70	Childhood onset of stiff-man syndrome. <i>JAMA Neurology</i> , 2013 , 70, 1531-6	17.2	57
69	Striational antibodies in a paraneoplastic context. <i>Muscle and Nerve</i> , 2013 , 47, 585-7	3.4	27
68	Chronic pain as a manifestation of potassium channel-complex autoimmunity. <i>Neurology</i> , 2012 , 79, 1136-44	6.4	138
67	Adult-onset opsoclonus-myoclonus syndrome. <i>Archives of Neurology</i> , 2012 , 69, 1598-607		131
66	Diagnostic utility of NMO/AQP4-IgG in evaluating CNS inflammatory disease in Thai patients. <i>Journal of the Neurological Sciences</i> , 2012 , 320, 118-20	3.2	21
65	Potassium channel complex autoimmunity induced by inhaled brain tissue aerosol. <i>Annals of Neurology</i> , 2012 , 71, 417-26	9.4	17

64	Autoimmune epilepsy: clinical characteristics and response to immunotherapy. <i>Archives of Neurology</i> , 2012 , 69, 582-93		269
63	Stiff-man syndrome and variants: clinical course, treatments, and outcomes. <i>Archives of Neurology</i> , 2012 , 69, 230-8		180
62	Do not treat from CIS onset: evaluate disease course and prognosis first--yes. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 391-3	5	3
61	Effects of age and sex on aquaporin-4 autoimmunity. <i>Archives of Neurology</i> , 2012 , 69, 1039-43		67
60	Neuronal voltage-gated potassium channel complex autoimmunity in children. <i>Pediatric Neurology</i> , 2011 , 44, 275-81	2.9	49
59	Psychiatric manifestations of voltage-gated potassium-channel complex autoimmunity. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011 , 23, 425-33	2.7	33
58	Reply: A new case of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) with initial normal magnetic resonance imaging. <i>Brain</i> , 2011 , 134, e183-e183	11.2	183
57	Autoimmune myelopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2011 , 17, 776-99	3	5
56	Neural autoantibody evaluation in functional gastrointestinal disorders: a population-based case-control study. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 1452-9	4	12
55	Paraneoplastic encephalomyelopathies: pathology and mechanisms. <i>Acta Neuropathologica</i> , 2011 , 122, 381-400	14.3	112
54	Beneficial plasma exchange response in central nervous system inflammatory demyelination. <i>Archives of Neurology</i> , 2011 , 68, 870-8		145
53	Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. <i>Archives of Neurology</i> , 2010 , 67, 322-9		106
52	Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). <i>Archives of Neurology</i> , 2010 , 67, 1109-15		61
51	Autoimmune dementia: clinical course and predictors of immunotherapy response. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 881-97	6.4	132
50	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). <i>Brain</i> , 2010 , 133, 2626-34	11.2	232
49	Peripherin-IgG association with neurologic and endocrine autoimmunity. <i>Journal of Autoimmunity</i> , 2010 , 34, 469-77	15.5	26
48	Immunotherapy-responsive dementias and encephalopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2010 , 16, 80-101	3	26
47	Neural autoantibody profile of primary achalasia. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 307-11	4	49

46	An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. <i>Lancet Neurology, The</i> , 2010 , 9, 55-66	24.1	45
45	Intractable vomiting as the initial presentation of neuromyelitis optica. <i>Annals of Neurology</i> , 2010 , 68, 757-61	9.4	139
44	Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. <i>Archives of Neurology</i> , 2009 , 66, 1128-33		229
43	Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. <i>Archives of Neurology</i> , 2009 , 66, 1134-8		72
42	Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. <i>Archives of Neurology</i> , 2009 , 66, 268-71		18
41	Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. <i>Archives of Neurology</i> , 2009 , 66, 735-41		112
40	Stiff eyes in stiff-person syndrome. <i>Neurology</i> , 2009 , 72, 1877-8; author reply 1878	6.5	1
39	Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. <i>Archives of Neurology</i> , 2009 , 66, 1164-7		91
38	Uncertain BENEFIT of early interferon beta-1b treatment. <i>Lancet Neurology, The</i> , 2009 , 8, 970-1	24.1	6
37	Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. <i>Muscle and Nerve</i> , 2009 , 39, 87-90	3.4	104
36	Polymyoclonus, laryngospasm, and cerebellar ataxia associated with adenocarcinoma and multiple neural cation channel autoantibodies. <i>Archives of Neurology</i> , 2009 , 66, 1285-7		2
35	Neuromyelitis optica and non organ-specific autoimmunity. <i>Archives of Neurology</i> , 2008 , 65, 78-83		387
34	Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 988-92	6.9	74
33	Aquaporin-4 autoantibodies in a paraneoplastic context. <i>Archives of Neurology</i> , 2008 , 65, 629-32		143
32	Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. <i>Archives of Neurology</i> , 2008 , 65, 1341-6		131
31	Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. <i>Journal of Experimental Medicine</i> , 2008 , 205, 2473-81	16.6	280
30	Neuromyelitis optica: a new perspective. <i>Seminars in Neurology</i> , 2008 , 28, 95-104	3.2	27
29	Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. <i>Annals of Neurology</i> , 2008 , 63, 531-4	9.4	56

28	Heterogeneity of presentation and outcome in the Irish rapid-onset dystonia-parkinsonism kindred. <i>Movement Disorders</i> , 2007 , 22, 1325-7	7	29
27	Neuromyelitis optica: changing concepts. <i>Journal of Neuroimmunology</i> , 2007 , 187, 126-38	3.5	90
26	The spectrum of neuromyelitis optica. <i>Lancet Neurology</i> , 2007 , 6, 805-15	24.1	1584
25	Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. <i>Brain</i> , 2007 , 130, 1194-205	11.2	556
24	The pathology of MS: new insights and potential clinical applications. <i>Neurologist</i> , 2007 , 13, 45-56	1.6	80
23	Interferon beta in multiple sclerosis: how much BENEFIT?. <i>Lancet</i> , 2007 , 370, 363-4	40	11
22	Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. <i>Annals of Neurology</i> , 2006 , 59, 566-9	9.4	474
21	Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. <i>Archives of Neurology</i> , 2006 , 63, 964-8		560
20	Steroid-responsive encephalopathy associated with autoimmune thyroiditis. <i>Archives of Neurology</i> , 2006 , 63, 197-202		375
19	Brain abnormalities in neuromyelitis optica. <i>Archives of Neurology</i> , 2006 , 63, 390-6		563
18	Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. <i>Mayo Clinic Proceedings</i> , 2006 , 81, 1207-14	6.4	180
17	Inflammatory transverse myelitis: evolving concepts. <i>Current Opinion in Neurology</i> , 2006 , 19, 362-8	7.1	47
16	Neuromyelitis optica IgG status in acute partial transverse myelitis. <i>Archives of Neurology</i> , 2006 , 63, 1398-400		63
15	Amphiphysin autoimmunity: paraneoplastic accompaniments. <i>Annals of Neurology</i> , 2005 , 58, 96-107	9.4	227
14	IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. <i>Journal of Experimental Medicine</i> , 2005 , 202, 473-7	16.6	1662
13	Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort study. <i>Archives of Neurology</i> , 2004 , 61, 679-86		94
12	Bright red nuclei. <i>Neurology</i> , 2004 , 62, 619	6.5	
11	Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. <i>Annals of Neurology</i> , 2004 , 56, 303-6	9.4	183

10	Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. <i>Annals of Neurology</i> , 2004 , 56, 715-9	9.4	267
9	Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. <i>Movement Disorders</i> , 2004 , 19, 1482-5	7	83
8	A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. <i>Lancet, The</i> , 2004 , 364, 2106-12	40	2296
7	OKT3 neurotoxicity presenting as akinetic mutism. <i>Transplantation</i> , 2003 , 75, 1058-60	1.8	23
6	Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. <i>Annals of Neurology</i> , 2003 , 53, 580-7	9.4	239
5	The Oxfordshire Community Stroke Project classification: correlation with imaging, associated complications, and prediction of outcome in acute ischemic stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2003 , 12, 1-7	2.8	62
4	The Orpington Prognostic Scale within the first 48 hours of admission as a predictor of outcome in ischemic stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2003 , 12, 175-81	2.8	8
3	Reversible myelopathy in a 34-year-old man with vitamin B12 deficiency. <i>Mayo Clinic Proceedings</i> , 2002 , 77, 291-4	6.4	31
2	Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders614-631		
1	Identification of Caveolae-Associated Protein 4 Autoantibodies as a Biomarker of Immune-Mediated Rippling Muscle Disease in Adults. <i>JAMA Neurology</i> ,	17.2	1